Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Session Abstracts

Abstract P6-04-18: Evaluation of the molecular mechanisms behind fulvestrant resistant breast cancer

T Kirkegaard, SK Hansen, BE Reiter, BS Sorensen and AE Lykkesfeldt
T Kirkegaard
Danish Cancer Society Research Center, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SK Hansen
Danish Cancer Society Research Center, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BE Reiter
Danish Cancer Society Research Center, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BS Sorensen
Danish Cancer Society Research Center, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AE Lykkesfeldt
Danish Cancer Society Research Center, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.SABCS12-P6-04-18 Published December 2012
  • Article
  • Info & Metrics
Loading
Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX

Abstract

To study the mechanisms behind treatment resistance, we have previously established a large panel of antiestrogen resistant breast cancer cell lines based on the estrogen receptor (ER)-positive breast cancer cell line, MCF-7. It seems to be a general phenomenon that MCF-7 cells switch from ER driven to human epidermal growth factor receptor (HER) driven cell growth upon development of fulvestrant resistance. To obtain a broader knowledge of the resistance mechanisms, we have established four fulvestrant resistant subclones from the ER-positive breast cancer cell line, T47D.

The parental T47D cells were confirmed to be estrogen responsive and short-term treatment of the parental T47D cells with fulvestrant severely reduced cell growth as well as protein expression of ER and the estrogen regulated proteins, insulin-like growth factor 1 receptor alpha (IGF-1Rα) and progesterone receptor (PR). All four fulvestrant resistant cell lines had reduced mRNA and protein expression of HER1 and HER4 compared to T47D, while HER2 was highly up regulated in the fulvestrant resistant cell lines and ER was lost. No difference in response to the HER2 inhibitor trastuzumab or the specific HER2 kinase inhibitor AG825 was observed between the fulvestrant resistant cell lines and T47D, indicating that HER2 is not the main driver of fulvestrant resistance in T47D cells. We found no indication of involvement of the two classical signaling pathways downstream of the HER receptors (Ras/Raf/Erk and PI3K/Akt). However, the JNK inhibitor SP600125 preferentially inhibited growth of two tested fulvestrant resistant cell lines. Withdrawal of fulvestrant for several weeks did not result in regain of ER expression, or in change of HER receptor expression, supporting a stable resistant phenotype.

In conclusion, loss of ER expression explains the lack of effect of fulvestrant in the T47D fulvestrant resistant cell lines. Noteworthy, the observed over expression of HER2 in the fulvestrant resistant T47D cells does not seem to be the main driver of cell growth, as HER2 targeted therapies like trastuzumab and HER2 kinase inhibitor did not exert a preferential growth inhibition of resistant cells. These breast cancer cells with high endogenous HER2 expression will be used as a model mimicking HER2 positive breast cancer which does not respond to standard HER2 targeted therapies.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-04-18.

Back to top
Cancer Research: 72 (24 Supplement)
December 2012
Volume 72, Issue 24 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P6-04-18: Evaluation of the molecular mechanisms behind fulvestrant resistant breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract P6-04-18: Evaluation of the molecular mechanisms behind fulvestrant resistant breast cancer
T Kirkegaard, SK Hansen, BE Reiter, BS Sorensen and AE Lykkesfeldt
Cancer Res December 15 2012 (72) (24 Supplement) P6-04-18; DOI: 10.1158/0008-5472.SABCS12-P6-04-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P6-04-18: Evaluation of the molecular mechanisms behind fulvestrant resistant breast cancer
T Kirkegaard, SK Hansen, BE Reiter, BS Sorensen and AE Lykkesfeldt
Cancer Res December 15 2012 (72) (24 Supplement) P6-04-18; DOI: 10.1158/0008-5472.SABCS12-P6-04-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract P6-11-19: Efficacy and patient acceptability of the DigniCaP ScalpCooler to prevent hair loss in breast cancer patients receiving adjuvant chemotherapy
  • Abstract P6-13-07: Chemotherapy with and without trastuzumab or no treatment in elderly patients with HER2 amplified breast cancer at a single center
  • Abstract P6-14-05: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
Show more 3

Poster Session 6 - Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance

  • Abstract P6-04-28: Changes in BAG-1 expression level affect the Tamoxifen-induced apoptosis and Gegitinb-induced apoptosis in breast cancer cells
  • Abstract P6-04-29: Vitamin D induces expression of estrogen receptor and restores endocrine therapy response in estrogen receptor-negative breast cancer
  • Abstract P6-04-16: The role of RIP140 and FOXA1 in breast cancer endocrine sensitivity and resistance
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement